Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Paclitaxel, Carboplatin and Topotecan With Peripheral Blood Stem Cell Support in Extensive Stage Small Cell Cancer
NCT00003943Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Sep 1998
- Primary completion
- Nov 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, carboplatin and topotecan in small cell lung cancer (SCLC) and carcinoma of unknown primary (CUP), sponsored by Fox Chase Cancer Center. Primary endpoint: Progression-Free Survival at 1 year. Started Sep 1998; status: completed.
02
Drugs
paclitaxelcarboplatintopotecan
03
Conditions
small cell lung cancer (SCLC)carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00003943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003943.